Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 581 - 590 of 764 studies

Blood

Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B

Turning6 - A Clinical and Neurodevelopmental follow up of EPIPEG participants at 60 months (Turning6)

Cancer and neoplasms

A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (TI-NDMM)-DREAMM-10 (DREAMM-10)

Musculoskeletal

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-45, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-45 (ELEVATE-45)

Cancer and neoplasms

A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with ABBV-400 in Subjects with Metastatic Colorectal Cancer (M24-533 (AndroMETa-CRC-533))

Predicting the Pain Outcome of Surgery for Endometriosis (PrePOSE)

Safety and Clinical Performance of the Drug Eluting Resorbable Coronary MAGnesium Scaffold System (Freesolve®) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries. (BIOMAG II)

Cancer and neoplasms

An Open-Label, Phase 2 study to evaluate safety, tolerability and preliminary activity of the CTPS1 inhibitor STP938 in adult subjects with high risk essential thrombocythaemia who are resistant to or intolerant of hydroxycarbamide therapy (STP938-301(VECTRA))

Eye

A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration And Fellow Eye Treatment Substudy

Unmasking concealed arrhythmia syndromes (RASE BRUGADA GEL)